256 related articles for article (PubMed ID: 17176072)
1. P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
Acharya P; Tran TT; Polli JW; Ayrton A; Ellens H; Bentz J
Biochemistry; 2006 Dec; 45(51):15505-19. PubMed ID: 17176072
[TBL] [Abstract][Full Text] [Related]
2. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
[TBL] [Abstract][Full Text] [Related]
3. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Biochem Biophys Res Commun; 2001 Nov; 289(2):580-5. PubMed ID: 11716514
[TBL] [Abstract][Full Text] [Related]
4. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
5. If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?
Lumen AA; Acharya P; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2010 Feb; 38(2):260-9. PubMed ID: 19889884
[TBL] [Abstract][Full Text] [Related]
6. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km.
Bentz J; Tran TT; Polli JW; Ayrton A; Ellens H
Pharm Res; 2005 Oct; 22(10):1667-77. PubMed ID: 16180124
[TBL] [Abstract][Full Text] [Related]
7. The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.
Tran TT; Mittal A; Aldinger T; Polli JW; Ayrton A; Ellens H; Bentz J
Biophys J; 2005 Jan; 88(1):715-38. PubMed ID: 15501934
[TBL] [Abstract][Full Text] [Related]
8. Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells.
Meng Z; Ellens H; Bentz J
Drug Metab Dispos; 2017 Feb; 45(2):190-197. PubMed ID: 27856526
[TBL] [Abstract][Full Text] [Related]
9. Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.
Agnani D; Acharya P; Martinez E; Tran TT; Abraham F; Tobin F; Ellens H; Bentz J
PLoS One; 2011; 6(10):e25086. PubMed ID: 22028772
[TBL] [Abstract][Full Text] [Related]
10. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
[TBL] [Abstract][Full Text] [Related]
11. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
12. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
[TBL] [Abstract][Full Text] [Related]
14. Case Study 8: Status of the Structural Mass Action Kinetic Model of P-gp-Mediated Transport Through Confluent Cell Monolayers.
Bentz J; Ellens H
Methods Mol Biol; 2021; 2342():737-763. PubMed ID: 34272715
[TBL] [Abstract][Full Text] [Related]
15. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein.
Bain LJ; LeBlanc GA
Toxicol Appl Pharmacol; 1996 Nov; 141(1):288-98. PubMed ID: 8917702
[TBL] [Abstract][Full Text] [Related]
16. Thyroid hormone export from cells: contribution of P-glycoprotein.
Mitchell AM; Tom M; Mortimer RH
J Endocrinol; 2005 Apr; 185(1):93-8. PubMed ID: 15817830
[TBL] [Abstract][Full Text] [Related]
17. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
18. Effect of benzo[a]pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer.
Sugihara N; Toyama K; Michihara A; Akasaki K; Tsuji H; Furuno K
Toxicology; 2006 Jun; 223(1-2):156-65. PubMed ID: 16647797
[TBL] [Abstract][Full Text] [Related]
19. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption.
Dey S; Gunda S; Mitra AK
J Pharmacol Exp Ther; 2004 Oct; 311(1):246-55. PubMed ID: 15175422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
